Class Action Alleges Misrepresentation by Corcept Therapeutics Ahead of Drug Approval Decision
- A class action lawsuit alleges Corcept Therapeutics misled investors about the approval prospects of relacorilant before a critical FDA decision.
- The FDA warned Corcept about insufficient clinical data, contradicting the company's optimistic public statements regarding its drug's prospects.
- Following an FDA rejection, Corcept's stock price plummeted, raising claims of violations regarding transparency and misrepresentation to investors.
Class Action Lawsuit Targets Corcept Therapeutics Over Regulatory Misrepresentation
A class action lawsuit has surfaced against Corcept Therapeutics Inc., spotlighting troubling allegations about the company’s conduct prior to a critical regulatory decision regarding its lead product, relacorilant. Filed by Hagens Berman, a well-known shareholder rights law firm, the complaint claims Corcept misled investors about the approval prospects of relacorilant from October 31, 2024, to December 30, 2025. Critics argue that Corcept's assurances of substantial support for the drug’s New Drug Application (NDA) contradicted private warnings issued by the FDA regarding insufficient clinical data. The case, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Incorporated, underscores significant concerns regarding transparency and regulatory compliance.
The crux of the lawsuit is a striking disconnect between Corcept's public statements and the private advisories from the FDA. Reed Kathrein, the Hagens Berman partner leading the investigation, emphasizes the gap between Corcept’s optimistic announcements about their drug's prospects and the agency's clear apprehensions. In particular, the FDA cautioned that any NDA submission should be accompanied by more robust evidence of the drug's effectiveness, prompting a discussion about the governance and accountability of the pharmaceutical company. Following these communications, Corcept’s decision to proceed with the NDA appears increasingly questionable, raising alarms among investors over a misrepresentation of the company's regulatory standing.
The situation escalates dramatically with Corcept's December 31, 2025 announcement that it received a Complete Response Letter (CRL) from the FDA, which indicates the agency’s refusal to approve the drug due to unresolved questions regarding its benefit and risk profiles. The disclosure of this information triggers a catastrophic drop in CORT’s stock price, plummeting from $70.20 to $34.80 in a single trading session and wiping out over $3.6 billion in market value for the company. This catastrophic event reinforces claims within the lawsuit that Corcept violated the Securities Exchange Act of 1934 by allegedly concealing crucial information from investors regarding the likelihood of approval and the efficacy of relacorilant.
In the aftermath of these revelations, stakeholders are encouraged to seek guidance from Hagens Berman regarding potential claims. The allegations against Corcept underline the critical importance of transparency in the pharmaceutical industry, particularly regarding drug approval processes, and raise broader questions about how companies communicate risks to their investors. Investors affected by the situation are advised to consider the implications of this lawsuit, which will likely unfold in the coming months as legal proceedings progress.
